Prof. Dr. Paul-Georg Germann

Angestellt, Global Head, Chemical & Preclinical Safety (CPS), Merck Health Care KGaA, Merck Healthcare KGaA, Darmstadt, Germany

Darmstadt, Deutschland

Fähigkeiten und Kenntnisse

Pharmazeutika
Organisation
Unternehmensführung
Changemanagement
Change Management
Veränderungsmanagement
Novartis
Altana
Elidel
Gleevec
Daxas)
Pharmaindustrie
Tiere
Lehre
Bildung
Advisory board member (FhG
Preclinical Risk Assessment of Pharmaceuticals
Toxicopathology
Pantoprazol
Hochschulprofessor an der tierärztlichen Hochschul
AbbVie Deutschland GmbH
Forschung und Entwicklung
Wissenschaft
Englische Sprache

Werdegang

Berufserfahrung von Paul-Georg Germann

  • Bis heute 6 Jahre und 6 Monate, seit Nov. 2017

    Global Head, Chemical & Preclinical Safety (CPS), Merck Health Care KGaA

    Merck Healthcare KGaA, Darmstadt, Germany

    Strategically and content wise leading a global unit for Chemical and Preclinical Safety with 126 FTE, covering Preclinical Safety Assessment for all Aspects of Chemical and Preclinical Safety in the indication fields of Oncology, Immunooncology and Immunology. Chemical Safety Assessments for high performance materials with respect to ecotoxicology and REACH.

  • 3 Jahre und 10 Monate, Jan. 2014 - Okt. 2017

    Head of Preclinical Safety Germany, AbbVie GmbH & Co.KG, Germany

    AbbVie Deutschland GmbH & Co. KG
  • 1 Jahr und 3 Monate, Okt. 2012 - Dez. 2013

    Leading New Frontiers Science Europe for Takeda Pharmaceuticals

    Takeda Pharmaceuticals International AG

    Vice President New Frontier Science Europe Takeda Pharmaceuticals, September 2012 – Present, Europe Scope of New Frontier Science: Bring very early science and groundbreaking innovation from academia and start ups into the value stream of a large pharmaceutical company. Create value through leveraging international connections within the academic community. Looking for platform technologies, focused therapies or healthcare concepts.

  • 4 Jahre und 9 Monate, Jan. 2008 - Sep. 2012

    Leading Discovery to Proof of Concept Development Organisation

    Nycomed GmbH

    01.12.2007-30.09.2012: Vice President “Discovery to Proof of Concept Development” Organisation, Nycomed a Takeda Company, Constance, Germany (Lead of R&D organisation with 5 multinational sites (Germany, Denmark, India) and approx. 450 employees, annual budget responsibility: 80 Mio.€; 01.03.2007-30.11.2007: Managing director and Vice President of “In vivo Efficacy & Safety”, 73 colleagues from pharmacology department in Constance reporting directly to Prof. Dr. Germann (approx. 220 employees in total).

  • 2 Jahre und 7 Monate, Juni 2005 - Dez. 2007

    Managing Director Institute for Pharmacology & Preclinical Safety

    Altana Pharma

  • 6 Jahre, Juni 1999 - Mai 2005

    Head of Pathology

    Novartis
  • 8 Jahre und 5 Monate, Jan. 1991 - Mai 1999

    Senior Pathologist

    Byk Gulden Pharmaceuticals

  • 3 Jahre und 3 Monate, Okt. 1987 - Dez. 1990

    Scientific Assistant, Pathologist

    Fraunhofer-Gesellschaft

Ausbildung von Paul-Georg Germann

  • 6 Jahre und 6 Monate, Apr. 1994 - Sep. 2000

    Master of Science Appl.Toxicology

    Universitiy of Guilford

    Toxicology and Risk Assessment

  • 5 Jahre und 3 Monate, Okt. 1982 - Dez. 1987

    Veterinärmedizin

    Tierärztliche Hochschule Hannover

    Pathology Toxicological Pathology Tumor and cell differentiation

Sprachen

  • Deutsch

    -

  • Englisch

    Fließend

Interessen

Bussiness networking in Pharma R&D
Social & communication skills Model trains

21 Mio. XING Mitglieder, von A bis Z